Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- irinotecan liposomal
- Kineret (anakinra)
Interactions between your drugs
anakinra irinotecan liposomal
Applies to: Kineret (anakinra), irinotecan liposomal
GENERALLY AVOID: The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution. Interleukin-1 blockers should be discontinued if neutropenia or serious infection occurs.
References (3)
- (2001) "Product Information. Kineret (anakinra)." Amgen
- (2008) "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc
- (2009) "Product Information. Ilaris (canakinumab)." Novartis Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Abraxane
Abraxane is an antineoplastic medication used in the treatment breast cancer. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Onivyde
Onivyde (irinotecan liposomal) is an injectable prescription chemotherapy medicine that may be used ...
Tarceva
Tarceva (erlotinib) is a chemotherapy medicine used in the treatment of non-small cell lung cancer ...
Sutent
Sutent is a cancer medicine that is used to treat certain types of advanced or progressive tumors ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.